12.06
前日終値:
$11.83
開ける:
$12.08
24時間の取引高:
3.83M
Relative Volume:
0.86
時価総額:
$1.25B
収益:
$45.97M
当期純損益:
$-508.80M
株価収益率:
-2.2007
EPS:
-5.48
ネットキャッシュフロー:
$-382.65M
1週間 パフォーマンス:
+4.55%
1か月 パフォーマンス:
+25.63%
6か月 パフォーマンス:
+26.95%
1年 パフォーマンス:
-53.78%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
名前
Intellia Therapeutics Inc
セクター
電話
857-285-6200
住所
40 ERIE STREET, CAMBRIDGE, MA
NTLA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
NTLA
Intellia Therapeutics Inc
|
12.06 | 1.19B | 45.97M | -508.80M | -382.65M | -5.48 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-04-21 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2025-03-05 | 開始されました | H.C. Wainwright | Buy |
2025-02-28 | ダウングレード | Goldman | Neutral → Sell |
2025-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
2025-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2024-02-23 | ダウングレード | Goldman | Buy → Neutral |
2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
2023-04-13 | 開始されました | Canaccord Genuity | Buy |
2023-03-21 | 開始されました | Bernstein | Outperform |
2023-03-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
2023-01-24 | アップグレード | Citigroup | Sell → Neutral |
2023-01-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2022-10-11 | 開始されました | Morgan Stanley | Overweight |
2022-09-21 | 開始されました | JP Morgan | Overweight |
2022-09-01 | 開始されました | Citigroup | Sell |
2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
2022-06-16 | 開始されました | BofA Securities | Buy |
2022-04-28 | 開始されました | Credit Suisse | Outperform |
2022-02-18 | 開始されました | William Blair | Outperform |
2022-02-07 | アップグレード | Oppenheimer | Perform → Outperform |
2022-01-31 | 開始されました | Cowen | Outperform |
2022-01-07 | 開始されました | Piper Sandler | Overweight |
2021-10-05 | 開始されました | Guggenheim | Buy |
2021-09-24 | 開始されました | Stifel | Buy |
2021-06-28 | 繰り返されました | H.C. Wainwright | Buy |
2021-06-11 | 開始されました | H.C. Wainwright | Buy |
2021-05-07 | アップグレード | ROTH Capital | Neutral → Buy |
2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
2020-12-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2020-10-27 | 開始されました | Truist | Buy |
2020-10-14 | 開始されました | Wells Fargo | Overweight |
2020-09-18 | 開始されました | Goldman | Buy |
2020-02-28 | アップグレード | Oppenheimer | Perform → Outperform |
2020-02-14 | ダウングレード | Wedbush | Outperform → Neutral |
2019-11-01 | アップグレード | Raymond James | Mkt Perform → Outperform |
2019-07-09 | 開始されました | Robert W. Baird | Outperform |
2019-06-10 | 開始されました | ROTH Capital | Neutral |
2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
2019-04-12 | 開始されました | Evercore ISI | Outperform |
2018-11-02 | ダウングレード | Wedbush | Outperform → Neutral |
2018-10-29 | 開始されました | Credit Suisse | Neutral |
2018-09-21 | 開始されました | Raymond James | Mkt Perform |
2018-05-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
2018-03-08 | 開始されました | JMP Securities | Mkt Outperform |
2017-11-01 | 繰り返されました | Jefferies | Buy |
2017-06-22 | 再開されました | Jefferies | Buy |
2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
2016-08-05 | アップグレード | Jefferies | Hold → Buy |
すべてを表示
Intellia Therapeutics Inc (NTLA) 最新ニュース
Is Intellia Therapeutics Inc. a good long term investmentRapidly expanding wealth - Jammu Links News
What analysts say about Intellia Therapeutics Inc. stockOverwhelming financial success - Jammu Links News
What drives Intellia Therapeutics Inc. stock priceUnprecedented market success - Jammu Links News
Intellia Therapeutics: A High-Volatility, High-Reward Play in the CRISPR Revolution - AInvest
With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At ‘Buy’ (NTLA) - Seeking Alpha
Intellia Therapeutics Inc. Stock Analysis and ForecastHigh-profit capital plays - Jammu Links News
Regeneron and Intellia’s Gene Therapy Study for Hemophilia B: A Market Game-Changer? - TipRanks
Intellia Faces The Biotech Balancing Act As Shares Slide - Finimize
ATTR Amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com
Regeneron and Intellia’s Gene Therapy Study: A Potential Game-Changer for Hemophilia B - TipRanks
Intellia Therapeutics (NTLA) Soars 9.08% on Phase III Trial - AInvest
Possible Bearish Signals With Intellia Therapeutics Insiders Disposing Stock - simplywall.st
Intellia Therapeutics (NTLA) Receives a Buy from RBC Capital - The Globe and Mail
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Gene Editing Leader Intellia Expands Team with 23,800 Share RSU Grant Package - Stock Titan
Intellia Gains 29.8% in a Month: How Should You Play the Stock? - Nasdaq
Intellia Therapeutics Reports Inducement Grants under Nasdaq Lis - GuruFocus
Insider Sell: Eliana Clark Sells Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data - Insider Monkey
Insider Sell Alert: Jesse Goodman Sells Shares of Intellia Thera - GuruFocus
The Best Biotech Stocks to Buy - Morningstar
Intellia Therapeutics gets FDA RMAT status for its heart disorder treatment - MSN
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? - Yahoo Finance
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress - Insider Monkey
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress. - Yahoo Finance
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely? - Yahoo Finance
Intellia Therapeutics’ SWOT analysis: gene editing pioneer’s stock faces pivotal year - Investing.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
Intellia Reports Positive Three-Year Follow-up Data from Phase 1 CRISPR Trial in Hereditary Angioedema - CRISPR Medicine News
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential - Yahoo Finance
Intellia’s three-year HAE treatment data shows durability, Citizens JMP says - Investing.com Canada
FDA clears CSL’s swelling disease drug; Regeneron loses 23andMe auction - BioPharma Dive
Intellia Therapeutics (NTLA) Receives Reiterated Buy Rating with Stable Price Target | NTLA Stock News - GuruFocus
Intellia Therapeutics Announces Positive Phase 1 Trial Data - TipRanks
Intellia Therapeutics Says Potential Hereditary Angioedema Treatment Reduces Attacks - MarketScreener
Intellia Therapeutics Announces Positive Three-Year Data - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Ph - GuruFocus
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress - GlobeNewswire Inc.
Intellia Therapeutics Reports Promising Three-Year Follow-Up Data for Lonvo-z in Hereditary Angioedema Patients - Quiver Quantitative
Intellia Therapeutics’ SWOT analysis: gene editing stock faces pivotal year - Investing.com
Intellia Therapeutics Holds Annual Stockholders’ Meeting - TipRanks
California State Teachers Retirement System Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NTLA Stock News - GuruFocus
Intellia Therapeutics Expands CRISPR Team: 33,600 RSUs Granted to New Leadership - Stock Titan
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting - mx.advfn.com
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31% - sharewise
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline? - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Given New $54.00 Price Target at Canaccord Genuity Group - Defense World
Intellia Therapeutics (NTLA) Price Target Adjusted by Canaccord Genuity | NTLA Stock News - GuruFocus
Intellia Therapeutics Inc (NTLA) 財務データ
収益
当期純利益
現金流量
EPS
Intellia Therapeutics Inc (NTLA) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
Bhanji Muna | Director |
Jan 29 '25 |
Sale |
9.97 |
265 |
2,642 |
19,468 |
Dube Michael P | VP, Chief Accounting Officer |
Jan 03 '25 |
Sale |
12.18 |
1,372 |
16,711 |
45,640 |
BASTA JAMES | EVP, General Counsel |
Jan 03 '25 |
Sale |
12.18 |
7,074 |
86,161 |
74,497 |
Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '25 |
Sale |
12.18 |
9,557 |
116,404 |
87,666 |
大文字化:
|
ボリューム (24 時間):